Antibody Contract Manufacturing Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Reports
Tailored for companies operating in or entering the antibody contract manufacturing sector, this analysis highlights core growth drivers, risks, and innovation trends.
What Is The Current Outlook For The Antibody Contract Manufacturing Market?
The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $14.8 billion in 2024 to $16.79 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increased demand for monoclonal antibodies, shift towards personalized medicine, cost optimization, stringent regulatory requirements, globalization of biologics.
The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.79 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing r&d spending, expansion of bispecific and multispecific antibodies, rise of antibody-drug conjugates (adcs), increasing healthcare infrastructure, growing government initiatives. Major trends in the forecast period include digitalization and data analytics, advanced upstream technologies, novel downstream processing techniques, sustainability initiatives, contract development and manufacturing integration (CDMO).
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp
What Are The Driving Factors Impacting The Antibody Contract Manufacturing Market?
The rising number of clinical trials is expected to propel the growth of the antibody contract manufacturing market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The number of clinical trials involving antibody-based therapeutics or diagnostics expands, for high-quality antibodies, ensuring a timely and compliant supply for clinical trials. For instance, in May 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, in all 50 states of the United States and 221 countries, the number of registered clinical trials studies climbed from 399,499 in 2022 to 437,533 in 2023. Additionally, around 241,498 studies, or 53% of the total, were registered outside the United States, compared to 140,492 studies (31%) registered just in the United States. Therefore, the rising number of clinical trials is driving the growth of the antibody contract manufacturing market.
Analysis Of Major Segments Driving The Antibody Contract Manufacturing Market Growth
The antibody contract manufacturingmarket covered in this report is segmented —
1) By Product: Monoclonal Antibodies; Polyclonal Antibodies; Other Products
2) By Source: Mammalian; Microbial
3) Scale Of Operation: Preclinical; Clinical; Commercial
4) By End-User: Biopharmaceutical Companies; Research Laboratories; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies; Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies; Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies; Antibody-Drug Conjugates (ADCs); Fusion Proteins
What Are The Upcoming Trends Of Antibody Contract Manufacturing Market In The Globe?
Major companies operating in the antibody contract manufacturing market are focusing on developing innovation, such as single-use technology that minimizes cross-contamination risks and reduces operational costs. Single-use technology (SUT) refers to disposable components and systems used in biopharmaceutical manufacturing processes. For instance, in September 2024, Merck & Co., a US-based pharmaceutical company, launched the Mobius ADC Reactor designed to enhance the manufacturing of antibody-drug conjugates. A new single-use reactor specifically designed for antibody drug conjugate manufacturing significantly enhances production efficiency by 70% compared to traditional stainless steel or glass methods. Its single-use design minimizes cross-contamination risks and operational costs, allowing for faster turnaround times. Additionally, advanced film technology improves bag strength and leak resistance, ensuring the integrity of highly potent active pharmaceutical ingredients. This innovation supports biopharmaceutical companies in producing critical therapies more safely and efficiently.
Which Are The Top Players Involved In Antibody Contract Manufacturing Market?
Major companies operating in the antibody contract manufacturing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.
View the full antibody contract manufacturing market report here:
https://www.thebusinessresearchcompany.com/report/antibody-contract-manufacturing-global-market-report
Which Region Drives The Most Demand In The Antibody Contract Manufacturing Market?
North America was the largest region in the antibody contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310–496–7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment